{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:11Z","timestamp":1761894671109},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.beha.2007.10.001","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T19:56:20Z","timestamp":1204660580000},"page":"817-835","source":"Crossref","is-referenced-by-count":22,"title":["Supportive care in multiple myeloma"],"prefix":"10.1016","volume":"20","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.10.001_bib1","first-page":"29","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.001_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nm0297-151","article-title":"Breast cancer and osteolytic metastases: can bisphosphonates help?","volume":"3","author":"Siris","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib6","first-page":"5294","article-title":"The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway","volume":"58","author":"Shipman","year":"1998","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2007.10.001_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0145-2126(00)00087-4","article-title":"A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells","volume":"25","author":"Takahashi","year":"2001","journal-title":"Leukemia Research"},{"key":"10.1016\/j.beha.2007.10.001_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.10.001_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group","volume":"101","author":"Brincker","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00355241","article-title":"Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study","volume":"2","author":"Thurlimann","year":"1994","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib14","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib17","first-page":"211a","article-title":"Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients","volume":"100","author":"Myers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib18","unstructured":"Ludwig H, T\u00f3thov\u00e1 E, Hajek R. et\u00a0al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: second interim analysis [abstract]. EHA Congress 2007."},{"key":"10.1016\/j.beha.2007.10.001_bib19","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer Journal (Sudbury, Mass.)"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2007.10.001_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.10-90001-14","article-title":"Renal safety of ibandronate","volume":"10","author":"Jackson","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2007.10.001_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib22","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib23","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib24","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.beha.2007.10.001_bib25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01682343","article-title":"The role of bisphosphonates in the treatment of bone metastases\u2013the U.S. experience","volume":"4","author":"Harvey","year":"1996","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.beha.2007.10.001_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","article-title":"Ocular adverse effects associated with systemic medications: recognition and management","volume":"67","author":"Santaella","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.beha.2007.10.001_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2007.10.001_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.beha.2007.10.001_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0885-3924(91)90518-9","article-title":"Correlation of patient and caregiver ratings of cancer pain","volume":"6","author":"Grossman","year":"1991","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.beha.2007.10.001_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00366899","article-title":"Undertreatment of cancer pain: barriers and remedies","volume":"1","author":"Grossman","year":"1993","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib34","first-page":"1","article-title":"Report of a WHO Expert Committee","volume":"804","author":"Cancer pain relief and palliative care","year":"1990","journal-title":"World Health Organization Technical Report Series"},{"key":"10.1016\/j.beha.2007.10.001_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/94.4.248","article-title":"COX-2 inhibitors: cancer trials test new uses for pain drug","volume":"94","author":"Michalowski","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2007.10.001_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3322\/canjclin.44.5.263","article-title":"The management of cancer pain","volume":"44","author":"Cherny","year":"1994","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.beha.2007.10.001_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY","volume":"77","author":"Birgegard","year":"2006","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10428199809068565","article-title":"The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma","volume":"29","author":"Musto","year":"1998","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.10.001_bib39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2141.1992.tb06939.x","article-title":"Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production","volume":"82","author":"Beguin","year":"1992","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/sonc.2002.33533","article-title":"Anemia of hematologic malignancies: what are the treatment options?","volume":"29","author":"Ludwig","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib41","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1182\/blood.V78.10.2564.2564","article-title":"Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin","volume":"78","author":"Means","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib42","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib44","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.155.19.2069","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial","volume":"155","author":"Garton","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"International Journal of Clinical & Laboratory Research"},{"key":"10.1016\/j.beha.2007.10.001_bib46","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib47","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","article-title":"Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma","volume":"70","author":"Silvestris","year":"1995","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.beha.2007.10.001_bib49","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","article-title":"Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis","volume":"58","author":"Musto","year":"1997","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.3690.3690","article-title":"Evaluation of traditional and novel predictive markers of anemia response to recombinant human erythropoietin (rh-Epo) in patients with multiple myeloma and lymphoma: emerging role of functional iron deficiency","volume":"104","author":"Katodritou","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.10.001_bib53","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib54","first-page":"141","article-title":"Erythropoietin and iron","volume":"47","author":"Sunder-Plassmann","year":"1997","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.beha.2007.10.001_bib55","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib56","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","article-title":"Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin","volume":"73","author":"Leitgeb","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib57","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.10.001_bib60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2007.10.001_bib61","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib62","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/0277-5379(91)90248-C","article-title":"Overall versus tumor-related survival in multiple myeloma. German Myeloma Treatment Group","volume":"27","author":"Peest","year":"1991","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib63","first-page":"214","article-title":"Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies","volume":"73","author":"Massaia","year":"1988","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.beha.2007.10.001_bib64","first-page":"282","article-title":"Immunosuppression and infection in multiple myeloma","volume":"13","author":"Jacobson","year":"1986","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.beha.2007.10.001_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/10428199809050943","article-title":"Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato oncological patients","volume":"30","author":"Salutari","year":"1998","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2007.10.001_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1700621","article-title":"Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation","volume":"19","author":"Kolbe","year":"1997","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2007.10.001_bib68","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for immunoglobulin replacement therapy in multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2007.10.001_bib69","first-page":"219","volume":"42","author":"Bezares","year":"1997","journal-title":"Sangre (Barc.)"},{"key":"10.1016\/j.beha.2007.10.001_bib70","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib72","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/42.4.497","article-title":"In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis","volume":"42","author":"Lass-Florl","year":"1998","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.beha.2007.10.001_bib73","first-page":"862","article-title":"Infections caused by filamentous fungi in patients with haematologica malignancies. A report of 391 cases by GIMEMA Infection Program","volume":"86","author":"Pagano","year":"2001","journal-title":"Haematologia"},{"key":"10.1016\/j.beha.2007.10.001_bib74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0003-4975(97)00858-8","article-title":"Surgical management of invasive pulmonary aspergillosis in neutropenic patients","volume":"64","author":"Bernard","year":"1997","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.beha.2007.10.001_bib75","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001813-199606000-00003","article-title":"Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia","volume":"7","author":"Aviles","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.beha.2007.10.001_bib76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-121-7-199410010-00004","article-title":"Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial","volume":"121","author":"Maher","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9343(96)90006-6","article-title":"Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia","volume":"100","author":"Anaissie","year":"1996","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beha.2007.10.001_bib78","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jcp.32.1.56","article-title":"Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual","volume":"32","author":"Payne","year":"1979","journal-title":"Journal of Clinical Pathology"},{"key":"10.1016\/j.beha.2007.10.001_bib79","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib80","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","article-title":"Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro","volume":"85","author":"Carano","year":"1990","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2007.10.001_bib81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00520-003-0477-1","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.beha.2007.10.001_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.beha.2007.10.001_bib84","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(85)90848-7","article-title":"Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids\/calcitonin in treatment of cancer-associated hypercalcaemia","volume":"2","author":"Ralston","year":"1985","journal-title":"Lancet"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T15:59:08Z","timestamp":1588435148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1521692607000758"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.10.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}